KURA Kura Oncology, Inc.
Price Chart
Executive Summary
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up. The data strengthen the case for ziftomenib as a combination backbone, but the stock has historically not moved significantly on similar clinical updates (T+20 avg alpha +0.22% over last 5 settled reports).
Actionable Insight
The publication in Blood provides peer-reviewed validation of the combination data, but the stock has historically shown muted reactions to clinical updates (T+20 avg alpha +0.22%). Watch for KOMET-017 Phase 3 data readouts and potential FDA filing for the combination regimen as the next catalysts.
Key Facts
- 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
- 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
- Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
- 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose
- Low rates of differentiation syndrome (3%) and QTc prolongation (1 case) observed
- Ziftomenib (KOMZIFTI) is FDA-approved as monotherapy for R/R NPM1-m AML
- KOMET-017 Phase 3 trials in newly diagnosed NPM1-m and KMT2A-r AML are ongoing
Financial Impact
No financial figures provided in press release; clinical data supports potential label expansion into combination therapy, which could expand addressable market beyond monotherapy
Risk Factors
- Combination regimen is investigational and not yet FDA-approved
- Differentiation syndrome boxed warning remains a safety concern
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Phase 3 trials may fail to replicate Phase 1b results
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305195 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
2d ago
|
Press Release
| $8.66 awaiting T+1 | awaiting T+1 | — | $8.70 (+0.58%) |
|
Jun 2, 2026
3d ago
|
Press Release
| $8.97 $8.66 | ▼ −3.51% | ▼ −2.82% | $8.70 (−2.95%) |
|
May 26, 2026
9d ago
|
DEFA14A
| — | awaiting T+1 | — | — |
|
May 26, 2026
10d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 22, 2026
13d ago
|
Insider Cluster
| $10.41 $10.39 | ▼ −0.19% | ▼ −0.15% | $8.70 (−16.38%) |
|
May 12, 2026
23d ago
|
8-K
| $9.48 $9.48 | · 0.00% | ▲ +0.00% | $8.70 (−8.18%) |
|
May 12, 2026
24d ago
|
Press Release
| $9.68 $9.48 | ▼ −2.07% | ▼ −2.64% | $8.70 (−10.07%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $9.68 $9.78 | ▲ +1.03% | ▲ +1.22% | $8.70 (−10.07%) |
|
Apr 10, 2026
7w ago
|
DEFA14A
| $8.72 $9.14 | ▲ +4.82% | ▲ +3.61% | $8.70 (−0.17%) |
|
Mar 5, 2026
13w ago
|
8-K
| $8.51 $8.96 | ▲ +5.29% | ▲ +6.60% | $8.70 (+2.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access